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Nonmotor symptoms (NMS) like neuropsychiatric symptoms, sleep disturbances or autonomic symptoms are a commonfeature
of Parkinson’s disease (PD). To explore the existence of groups of NMS and to relate them to PD characteristics, 71 idiopathic
non-demented PD out-patients were recruited. Sleep was evaluated by the PD Sleep Scale (PDSS). Several neuropsychiatric,
gastrointestinal and urogenital symptoms were obtained from the NMSQuest. Sialorrhea or dysphagia severity was obtained from
the Uniﬁed PD Rating Scale activities of daily living section. MADRS depression scale was also administered. Exploratory factor
analysisrevealedthepresenceof5factors,explaining70%ofvariance.TheﬁrstfactorincludedPDSSmeasurementofsleepquality,
nocturnal restlessness, oﬀ-related problems and daytime somnolence; the second factor included nocturia (PDSS) and nocturnal
activity; the third one included gastrointestinal and genitourinary symptoms; the forth one included nocturnal psychosis (PDSS),
sialorrhea and dysphagia (UPDRS); and the last one included the MADRS score as well as neuropsychiatric symptoms. Sleep
disorders correlated with presence of wearing-oﬀ,n o c t u r i aw i t ha g e>69 years, and nocturnal psychosis with levodopa equivalent
doseorUPDRS II score. Neuropsychiatric symptoms correlated with UPDRS II+III score andnon-tricyclic antidepressants. These
results support the occurrence of signiﬁcant NMS grouping in PD patients.
1.Introduction
Nonmotor symptoms (NMSs) are a frequent feature of
Parkinson’s disease (PD), aﬀecting up to 60% of patients
[1, 2]. These symptoms are usually underrecognized and
undertreated, thus leading to a reduced quality of life,
to comorbidities, and to precocious institutionalization or
hospitalization [2]. Recently, NMS management has been
recognized as an important unmet need in PD [3].
NMSs comprise a large variety of symptoms including,
among others, neuropsychiatric and sleep disturbances,
autonomic dysfunction, and gastrointestinal or sensory
symptoms [1, 4]. NMSs can be assessed by several tools
speciﬁcally designed for these symptoms, includingthe NMS
questionnaire (NMSQuest) [4], the uniﬁed PD rating scale
(UPDRS) [5] and the PD sleep scale (PDSS) [6].
Pathophysiologically, NMS may be related to both
dopaminergic and nondopaminergic alterations. For exam-
ple, PET studies reported dopamine dysfunction at the
hypothalamus [7]. Degeneration of cholinergic, adrenergic,
or serotoninergic pathway could also contribute to NMS
genesis [8]. Moreover, NMS can precede motor symptoms
and thus PD diagnosis [2].
Several studies have suggested that NMS coexist, thus
highlighting the possibility of NMS grouping [1, 4, 9].
Identiﬁcation of such groups can be important for research2 Parkinson’s Disease
on underlying disease mechanisms, since homogeneous
groups of patients are more likely to share pathological and
genetic features [10]. Therefore, we conducted the present
pilot study to explore the existence of NMS groups as well
as to relate them to PD characteristics or pharmacological
treatment.
2.Methods
2.1.StudySample. PD patients were recruited from a tertiary
outpatient clinic to conduct a study to validate sleep logs
use in PD [11]. To be included, the subjects had to fulﬁll
the United Kingdom Parkinson’s Disease Society Brain Bank
criteria [12]. Patients with minimental state examination
(MMSE) score <25 points [13] were excluded.
The protocol conformed the principles enumerated in
the Helsinki Declaration and was approved by the Institu-
tionalReviewBoard.Allsubjectssignedaninformed consent
after full explanation of the procedures.
2.2. PD and NMS Evaluation. PD patients were subjected
to cognitive, psychiatric, and motor evaluation including an
MMSE [14], a Montgomery-Asberg Depression Rating scale
(MADRS) [15], and UPDRS [5]. Medication records were
used to calculated levodopa equivalent daily dose (LDED)
according to the usual formula [16]. Severities of sialorrhea
or dysphagia were obtained from items no. 6 or no. 7 of the
UPDRS II (activities of daily living) section.
Presence ofsleepdisturbances wasevaluatedbythe PDSS
[6]. PDSS items were grouped according to domain: sleep
quality (items 1 to 3); nocturnal restlessness (items 4 and 5);
nocturnal psychosis (items 6 and 7), nocturia (item 8);
nocturnal motor symptoms (items 9 to 13) and daytime
somnolence (items 14 and 15) (25).
NMSQuest was also administered to patients [1]. Ques-
tions were grouped according to the following domains:
gastrointestinal motility problems (items 5–7); urinary dys-
function (items 8-9) or neuropsychiatric disorders (i.e.,
apathy, memory, or attention disorders, items 12–15). Other
domains were not included in the analysis.
All participants were instructed to wear an actigraphy
deviceduring 7days(MicroMini-Motionlogger, Ambulatory
MonitoringInc,NY,USA)whichservedforthecalculationof
nighttime activity.
2.3. Statistical Analysis. Categorical data were compared
using chi-square and numerical variables by an analysis
of variance (ANOVA). Exploratory factor analysis (EFA)
(with principal components as extraction methods followed
by oblique rotation) was ﬁrst employed to build NMS
factors, since between-factor correlations could not be ruled
out a priori [17] .T h en u m b e ro ff a c t o r sw a sd e t e r m i n e d
by inspection of the screen plot and Kaiser’s criterion
(i.e., eigenvalue >1), and factor scores were calculated.
Between-factors correlations were calculated and if all of
them were <0.35 (i.e., a determination coeﬃcient ∼15%),
independency was concluded. In this case, EFA was repeated
but employing varimax rotation, which allows better factor
deﬁnition.
Table 1: Patients characteristics.
Males/Females (%) 36 (51)/35 (49)
Age (Mean ± SD) 68.5 ± 8.7
UPDRS II+III in ON (Mean ± SD) 29.1 ± 14.1
Hoehn&Yahr score
I 10 (14)
I.5 13 (18)
II/II.5 23 (32)
III 16 (23)
IV/V 9 (13)
PD duration (Mean ± SD) 7.7 ± 5.7 years
(range: 1–20)
No dopaminergic therapy (%) 15 (21)
Levodopa (%) 45 (63)
Dopamine agonists(%) 42 (60)
LDED (Mean ± SD) 596 ± 462
Diskinesias (%) 34 (47)
Wearing oﬀ (%) 35 (49)
LDED: levodopa equivalent daily dose; PD: Parkinson’s Disease; SD: stan-
dard deviation.
Sampling adequacy was evaluated by Kaiser-Meyer-
Olkin (KMO) score, which had to be >0.600. For the
evaluation of model validity, communalities were calculated,
which had to be >0.50 for all variables. Finally, bivariate
and multivariate analyses were employed to disclose the
independent variables related to factor scores. For these
analyses, factor scores were categorized to their medians.
The following independent variables were considered: age,
sex, PD duration, UPDRS II total score, UPDRS II+III
score, presence of dyskinesias ormotorﬂuctuations (UPDRS
IV), administration of levodopa and intake of dopamine
agonists, monoamine oxidase inhibitors, catechol-O-methyl
transferase inhibitors, antimuscarinics, amantadine, tricyclic
or nontricyclic antidepressants, benzodiazepines, and hyp-
notics.
Bivariateanalyses were carried outwithchi-square statis-
tic. A multivariate model with factors scores as dependent
variables was constructed by forward logistic regression.
Only correlates with a signiﬁcance level in the bivariate
analyses were included as explanatory variables in the
models. These variables were dichotomized to their medians
to help interpretation. Goodness of ﬁt was explored by
the Hosmer and Lemeshow score, which was >0.70 in all
cases. Potential interactions and multicolinearity were tested
for the models, and none was found. All analyses were
performed by SPSS v.15 (SPSS Inc. Chicago, Ill).
3.Results
Seventy-onepatients were includedin this study.A summary
of their characteristics is shown in Table 1.E F Ar e v e a l e dt h e
presence of 5 factors with eigenvalues >1 and that explained
70% of variance. KMO score was 0.620. All communalities
were >0.50. These results support the validity of the model.Parkinson’s Disease 3
Table 2: Results of the exploratory factor analysis.
Items Factor 1 Factor 2 Factor 3 Factor 4 Factor 5
Sleep quality (PDSS) 0.789
Noct. restlessness (PDSS) 0.839
Oﬀ-related problems (PDSS) 0.636
Daytime somnolence (PDSS) 0.538
Nocturia (PDSS) 0.839
Noct. Activity (actigraphy) 0.654
GU symptoms (NMSQ) 0.935
GI Motility disorders (NMSQ) 0.939
Noct. Psychosis (PDSS) 0.572
Sialorrhea (UPDRS) 0.809
Dysphagia (UPDRS) 0.668
MADRS 0.911
NPS symptoms (NMSQ) 0.866
Variance explained by factor 27.6 13.2 11.9 9.8 8.0
GU: genitourinary; GI: gastrointestinal; MADRS: montgomery-Asberg depression Rating scale; NPS: neuropsychiatric symptoms.
Factors loadings are shown in Table 2.T h eﬁ r s tf a c t o r
included PDSS measurement of sleep quality, nocturnal
restlessness, oﬀ-related problems, and daytime somnolence
and was thus named “sleep disorders.” The second factor
included nocturia (PDSS) and nocturnal activity and was
named as “nocturia.” The third one includedgastrointestinal
and genitourinary symptoms (“autonomic disturbances”).
The fourth one comprised nocturnal psychosis (PDSS),
sialorrhea, and dysphagia (UPDRS) and was named as
“nocturnal psychosis.” The ﬁfth one included MADRS score
as well as neuropsychiatric symptoms, being labeled as
“neuropsychiatric symptoms.” Only the latter factor score
showed some statistically signiﬁcant correlations with sleep
disorders factor score (r = 0.26) or with autonomic
disturbances factor score (r = 0.29). As all correlation
coeﬃcients were below 0.35, EFA with varimax rotation was
employed, which conﬁrmed the factor structure.
Females showed lower scores for nocturnal psychosis
(F =− 0.26 ± 0.11, M = 0.27 ± 0.20, P<. 05) or higher for
NPSsymptoms (F = 0.27±0.17,M =− 0.27±0.15,P<. 05).
Subjectsover 69 years old had higher nocturia scores (0.41 ±
0.16 versus −0.39 ± 0.14). Subjects with UPDRS II+III in
ON-state >26 had higher scores for NPS symptoms factor
(0.34 ± 0.19 versus −0.33 ± 0.12, P<. 01). Subjects with
UPDRS II in ON-state > 9 had higher NPS symptoms factor
score (−0.33 ± 19 versus 0.32 ± 0.11, P<. 01). Subjects
with time from PD onset >7 years had higher scores sleep
disorders factor (0.26 ± 0.17 versus −0.25 ± 0.15, P<. 05),
for nocturnal psychosis (0.37 ± 0.19 versus −0.36 ± 0.11,
P<. 05) or for NPS symptoms (0.25 ± 0.18 versus −0.24 ±
0.15, P<. 05). Subjects with wearing-oﬀ had higher sleep
disorders factor (0.34 ± 0.17 versus −0.31 ± 0.14, P<. 01).
Subjects with levodopa equivalent dose >625mg/day had
higher scores on sleep disorders (0.21 ± 0.20 versus −0.18 ±
0.10, P<. 05) or on nocturnal psychosis (0.36 ± 0.19 versus
−0.31 ± 0.19). Subjects on antipsychotics had higher scores
on nocturnal psychosis factor (1.16 ± 0.41 versus −0.66 ±
0.12, P<. 05). Subjects on nontricyclic antidepressants had
higher scores for NPS symptoms score (0.35 ± 0.14 versus
−0.15 ± 0.10, P<. 05).
Variables independently related to categorized factor
scores were then analysed by logistic regression. Results are
shown in Table 3. Sleep disorders correlated with the pres-
ence of wearing-oﬀ,n o c t u r i aw i t ha g e>69 years, nocturnal
psychosis with levodopaequivalent dose, or UPDRS II score,
while neuropsychiatric symptoms correlated with UPDRS
II+III score, or non-tricyclic antidepressants. Autonomic
disturbance symptoms did not show any correlation with
other factors.
4.Discussion
The present pilot exploratory study suggests the existence
of signiﬁcant NMS grouping in PD. Such groups, which are
usually named “factors” included sleep disorders, nocturia,
autonomic disturbance symptoms, nocturnal psychosis, and
neuropsychiatric symptoms. These results can contribute to
the understanding of NMS underlying mechanism. Indeed,
based on the herein reported correlations of NMS with
PD characteristics or pharmacological treatments some
pathophysiological considerations can be entertained.
Before further discussion, the limitations of the present
study must be mentioned. Firstly, the sample size was small,
although it included a wide range of subjects and was suﬃ-
cient to allow sampling adequacy for factor analysis. While
grouping of motor symptoms in PD has been extensively
explored in the past years [18], to the best of our knowledge,
thereare no such studiesfocusing onNMS.Ourstudy, which
was conducted in a small precollected database, provides
a preliminary impression on the subject, which should be
conﬁrmed in larger studies. We believe that they can be
useful for generating hypothesis as well as for planning and
interpreting future studies.
Secondly, evaluation of NMS was performed only by
subjective scales which in some cases have only received par-
tial validation, for example, PDSS or NMSQuest. Moreover,4 Parkinson’s Disease
Table 3: Variables independently related to categorized factor scores.
Factor Independent variables OR (95% CI) P value
Sleep disorders Wearing-oﬀ 4.18 (1.54–11.34) .005
Nocturia Age >69 years 5.45 (1.96–15.17) .001
Autonomic disturbances — — —
Nocturnal psychosis LDED >625 mg/day 3.99 (1.39–11.38) .01
UPDRS II >9 2.91 (1.02–8.27) .045
NPS symptoms UPDRS II+III >26 4.07 (1.44–11.49) .008
Non-tricyclic antidepressants 5.85 (1.08–31.53) .04
LDED: levodopa equivalent daily dose. 95% CI = 95% conﬁdence interval.
dichotomous variables, such as those produced by the latter,
cannot be included in factor analysis as such. Thus, proxy
variables depicting numbers of neuropsychiatric, genitouri-
nary, or gastrointestinal symptoms had to be employed,
which may not reﬂect the true nature of these symptoms.
In addition, some important and frequent NMS such as
orthostatic hypotension, sexual dysfunction, leg swelling,
olfactory dysfunction, visual problems, sweating, pain and
fatigue, or weight loss could not be included in the analysis
because of the aforementioned reason. Moreover, many
factors were formed by less than 3 items, which could
aﬀect their stability. Future studies should therefore include
disaggregated items (i.e., not the number of gastrointestinal
symptoms but a measure of the intensity of each one
of them). It should be noted that the present study was
conducted before NMS development [19]. As this scale can
capture frequency and severity of NMS in PD, its use should
be important in future NMS grouping studies.
Keeping in mind these limitations, some theoretical
hypotheses about the diﬀerent NMS factors found can be
entertained. Subjective complaints of troubled sleep, such as
the ones captured by PDSS, have been related mainly to PD
severity or depression [6, 10, 20, 21]. In our study, presence
of wearing-oﬀ was the only variable independently related
to troubled sleep factor, which is consistent with previous
ﬁndings [21,22].Progressive neurodegenerationcausingloss
of long-term response to levodopa would lead to insuﬃcient
nighttime dopaminergic tone [23] thus providing a suitable
explanation for the ﬁndings. In turn, this suggests that
nighttime administration of controlled-release levodopa or
dopamine agonists or COMT inhibitors could constitute an
eﬀective treatment for sleep disorders in PD [24]. Indeed,
controlled-release ropinirole has been shown to increase
PDSS score [25].
Nocturia has been considered in the past to be related
to PD. Our results indicate that this may not be the case
and that nocturia is a consequence of normal aging and thus
should not be considered within the constellation of NMS in
PD. Indeed previous studies did not disclose any diﬀerence
between PD and healthy controls in this domain [26, 27].
Nocturnal psychosis, as subjectively evaluated by PDSS,
was closely related to sialorrhea and dysphagia. It is not the
ﬁrst time that such an odd correlation is reported, and it has
been previously related to antipsychotics intake [28]. This
appears not to be the case in the present study, as antipsy-
chotics were not statistically related to nocturnal psychosis
in the logistic analysis, while dopaminergic stimulation and
disease severity were. It can be possible that increased disease
severity is the underlying cause of both oral symptoms and
increased dopaminergic stimulation which in turn would
lead to psychotic symptoms [29].
Neuropsychiatric symptoms such as depression, apathy,
memory, or attention disorders were signiﬁcantly related to
disease severity, in line with previous ﬁndings [29]. The
detected relationship with non-tricyclic antidepressants can
be explained by the fact that they are usually used to
treat depression, thus probably revealing a protopathic bias.
Finally, gastrointestinal and genitourinary symptoms loaded
in the same factor, thus revealing a common origin, probably
autonomic dysfunction [30].
In conclusion, EFA found 5 groups of NMS, includ-
ing troubled sleep, nocturia, gastrointestinal/genitourinary
symptoms, sialorrhea/psychotic symptoms, and NPS symp-
toms, which were related to some PD characteristics. These
preliminary ﬁndings, resulting from a pilot exploratory
study, can be useful for hypothesis generation as well as for
planning of future studies.
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